Venlafaxine, Paroxetine and Milnacipran for Major Depressive Disorder: A Pragmatic 24-Week Study

10.4077/CJP.2014.BAC209

Hui-Yu Chuang；Yun-Hsuan Chang；Ling-Yi Cheng；Yu-Shan Wang；Shiou-Lan Chen；Shih-Heng Chen；Chun-Hsien Chu；I-Hui Lee；Po-See Chen；Tzung-Lieh Yeh；Yen-Kuang Yang；Ru-Band Lu

milnacipran ； paroxetine ； remission ； response ； venlafaxine

The Chinese Journal of Physiology

57卷5期（2014 / 10 / 31）

265 - 270

英文

Major depressive disorder (MDD), one of the most common psychiatric disorders in the world, is a serious, recurrent and chronic mental disorder, which is associated with significant psychosocial disability and economic burden. Until recently, short-term effectiveness of antidepressants has been measured in terms of patients' response to the medications in significantly reduced depressive symptoms. Remission, a long-term elimination of symptoms and the restoration of normal functioning, has become the primary outcome of therapy. In the current study, the efficacy of three frequently prescribed antidepressants, venlafaxine (75-225 mg/day), paroxetine (20 mg/day) and milnacipran (100 mg/day), used in treating 249 MDD patients with Hamilton Rating Scale of Depression (HRSD_(17)) scores higher than 16 was compared. Each patient was evaluated at week 0, 1, 2, 4, 8, 12, 16, 20 and 24 in a 24-week open-label study. Eighty-two patients took venlafaxine, 97 took paroxetine and 70 patients took milnacipran. No significant differences were found between the three groups in the response condition (HRSD_(17) scores decreased more than 50%) after 24 weeks of follow-up. For remission, the paroxetine was the least efficacious medication than either the milnacipran (HRSD_(17) ≤ 7) or the venlafaxine (HRSD_(17) ≤ 5) by the last observation carried forward (LOCF) analysis. Our results suggest that the absence of depressive symptoms alone may not be an indicator for MDD remission, but the duration of absent depressive symptoms may be a better indicator.

1. Fang, Y.C.,Chou, C.T.,Pan, C.C.,Hsieh, Y.D.,Liang, W.Z.,Chao,D.,Tsai, J.Y.,Liao, W.C.,Kuo, D.H.,Shieh, P.,Kuo, C.C.,Jan, C.R.,Shaw, C.F.(2011).Paroxetine-induced Ca2+ movement and death in OC2 human oral cancer cells.Chinese J. Physiol,54,310-317.
   連結：
2. Sahin, G.,Guner, I.,Yelmen, N.,Yaman, O.,Mengi, M.,Simsek, G.,Sipahi, S.(2011).Alterations of central hypercapnic respiratory response induced by acute central administration of serotonin reuptake inhibitor, fluoxetine.Chinese J. Physiol,54,356-366.
   連結：
3. Su, S.W.,Cherng, C.F.,Lin, Y.C.,Yu, L.(2007).Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice.Chinese J. Physiol,50,1-8.
   連結：
4. Akerblad, A.C.,Bengtsson, F.,von Knorring, L.,Ekselius, L.(2006).Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study.Int. Clin. Psychopharmacol,21,117-124.
5. Angst, J.(1999).Major depression in 1998: are we providing optimal therapy?.J. Clin. Psychiatry,60(Suppl 6),5-9.
6. Ansseau, M.,Demyttenaere, K.,Heyrman, J.,Migeotte, A.,Leyman, S.,Mignon, A.(2009).Objective: remission of depression in primary care The Oreon Study.Eur. Neuropsychopharmacol,19,169-176.
7. Brunello, N.,Mendlewicz, J.,Kasper, S.,Leonard, B.,Montgomery,S.,Nelson, J.,Paykel, E.,Versiani, M.,Racagni, G.(2002).The role of noradrenaline and selective noradrenaline reuptake inhibition in depression.Eur. Neuropsychopharmacol,12,461-475.
8. Davidson, J.R.,Meltzer-Brody, S.E.(1999).The underrecognition and undertreatment of depression: what is the breadth and depth of the problem?.J. Clin. Psychiatry,60(Suppl 7),4-11.
9. Fassone, G.,Trincia, V.,D'amato, A.e.a.(2003).A 2-year follow-up study of patients with unipolar depressive disorders; preliminary findings on 70 patients.Ital. J. Psychopathol,9,51-57.
10. Ferrier, I.N.(1999).Treatment of major depression: is improvement enough?.J. Clin. Psychiatry,60(Suppl 6),10-14.
11. Frank, E.,Prien, R.F.,Jarrett, R.B.,Keller, M.B.,Kupfer, D.J.,Lavori, P.W.,Rush, A.J.,Weissman, M.M.(1991).Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.Arch. Gen. Psychiatry,48,851-855.
12. Gourion, D.(2008).Antidepressants and their onset of action: a major clinical, methodological and pronostical issue.Encephale,34,73-81.
13. Hamilton, M.(1960).A rating scale for depression.J. Neurol. Neurosurg. Psychiatry,23,56-62.
14. Hermens, M.L.,van Hout, H.P.,Terluin, B.,Ader, H.J.,Penninx,B.W.,van Marwijk, H.W.,Bosmans, J.E.,van Dyck, R.,de Haan, M.(2007).Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial.BMC Med.,5,36.
15. Judd, L.L.,Akiskal, H.S.,Maser, J.D.,Zeller, P.J.,Endicott, J.,Coryell, W.,Paulus, M.P.,Kunovac, J.L.,Leon, A.C.,Mueller,T.I.,Rice, J.A.,Keller, M.B.(1998).Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.J. Affect. Disord,50,97-108.
16. Judd, L.L.,Akiskal, H.S.,Zeller, P.J.,Paulus, M.,Leon, A.C.,Maser, J.D.,Endicott, J.,Coryell, W.,Kunovac, J.L.,Mueller, T.I.,Rice, J.P.,Keller, M.B.(2000).Psychosocial disability during the long-term course of unipolar major depressive disorder.Arch. Gen. Psychiatry,57,375-380.
17. Keller, M.B.(2004).Remission versus response: the new gold standard of antidepressant care.J. Clin. Psychiatry,65(Suppl 4),53-59.
18. Kennedy, S.,McIntyre, R.,Fallu, A.,Lam, R.(2002).Pharmacotherapy to sustain the fully remitted state.J. Psychiatry Neurosci,27,269-280.
19. Kessler, R.C.,Berglund, P.,Demler, O.,Jin, R.,Koretz, D.,Merikangas, K.R.,Rush, A.J.,Walters, E.E.,Wang, P.S.(2003).The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).J. Am. Med. Assoc,289,3095-3105.
20. Lecrubier, Y.,Pletan, Y.,Solles, A.,Tournoux, A.,Magne, V.(1996).Clinical efficacy of milnacipran: placebo-controlled trials.Int. Clin. Psychopharmacol,11(Suppl 4),29-33.
21. Leinonen, E.,Lepola, U.,Koponen, H.,Mehtonen, O.P.,Rimon, R.(1997).Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.Acta. Psychiatr. Scand,96,497-504.
22. Lepine, J.P.,Gastpar, M.,Mendlewicz, J.,Tylee, A.(1997).Depression in the community: the first pan-European study DEPRES (Depression Research in European Society).Int. Clin. Psychopharmacol,12,19-29.
23. Macher, A.M.,Angritt, P.,Tuur, S.M.,Joshi, V.V.,Daly, M.J.,Henriques, U.V.,Landing, B.H.(1989).AIDS. Case for diagnosis series, 1988.Mil. Med.,154,M89-M99.
24. Macher, J.P.,Sichel, J.P.,Serre, C.,Von Frenckell, R.,Huck, J.C.,Demarez, J.P.(1989).Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders.Neuropsychobiology,22,77-82.
25. Nierenberg, A.A.,DeCecco, L.M.(2001).Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.J. Clin. Psychiatry,62(Suppl 16),5-9.
26. Owens, M.J.,Krulewicz, S.,Simon, J.S.,Sheehan, D.V.,Thase, M.E.,Carpenter, D.J.,Plott, S.J.,Nemeroff, C.B.(2008).Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine.Neuropsychopharmacology,33,3201-3212.
27. Puech, A.,Montgomery, S.A.,Prost, J.F.,Solles, A.,Briley, M.(1997).Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability.Int. Clin. Psychopharmacol,12,99-108.
28. Saiz-Ruiz, J.,Ibanez, A.,Diaz-Marsa, M.,Arias, F.,Padin, J.,Martin-Carrasco, M.,Montes, J.M.,Ferrando, L.,Carrasco, J.L.,Martin-Ballesteros, E.,Jorda, L.,Chamorro, L.(2002).Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.Prog. Neuropsychopharmacol. Biol. Psychiatry,26,1129-1134.
29. Sartorius, N.(2001).The economic and social burden of depression.J. Clin. Psychiatry,62(Suppl 15),8-11.
30. Sheehan, D.V.,Lecrubier, Y.,Sheehan, K.H.,Amorim, P.,Janavs, J.,Weiller, E.,Hergueta, T.,Baker, R.,Dunbar, G.C.(1998).The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J. Clin. Psychiatry,59(Suppl 20),22-57.
31. Thase, M.E.(1999).Redefining antidepressant efficacy toward long-term recovery.J. Clin. Psychiatry,60(Suppl 6),15-19.
32. Tran, P.V.,Bymaster, F.P.,McNamara, R.K.,Potter, W.Z.(2003).Dual monoamine modulation for improved treatment of major depressive disorder.J. Clin. Psychopharmacol,23,78-86.
33. Wu, Y.S.,Chen, Y.C.,Lu, R.B.(2007).Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan.J. Clin. Pharm. Ther.,32,353-363.
34. Zemancikova, A.,Torok, J.(2013).Diminished contractile responses of isolated conduit arteries in two rat models of hypertension.Chinese J. Physiol,56,230-235.
35. Zimmerman, M.,Posternak, M.A.,Chelminski, I.(2004).Defining remission on the Montgomery-Asberg depression rating scale.J. Clin. Psychiatry,65,163-168.
36. Zimmerman, M.,Posternak, M.A.,Chelminski, I.(2005).Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high?.J. Nerv. Ment. Dis.,193,170-175.
37. Zimmerman, M.,Posternak, M.A.,Chelminski, I.(2007).Heterogeneity among depressed outpatients considered to be in remission.Compr. Psychiatry,48,113-117.